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We introduce a new proliferation marker, securin (pituitary tumour-transforming 1 (PTTG1)), analysed in invasive ductal breast
carcinomas by cDNA microarrays and immunohistochemistry. In cDNA microarray of a total of 4000 probes of genes, securin was
revealed with a significant change in expression among the several proliferation-related genes studied. The value of securin as a
proliferation marker was verified immunohistochemically (n¼44) in invasive ductal breast cancer. In follow-up analyses of the sample
of patients, the prognostic value of securin was compared with the established markers of breast cancer proliferation, Ki-67 and
mitotic activity index (MAI). Our results of a small sample of patients suggest that low securin expression identifies a distinct subgroup
of more favourable outcome among patients with high Ki-67 immunoexpression or high MAI. In univariate analysis of Cox’s
regression, 10-unit increment of securin immunopositivity was associated with a 2.3-fold overall risk of death due to breast cancer and
a 7.1-fold risk of death due to breast cancer in the sample of patients stratified according to the cutoff points of 10 and 20% of securin
immunopositivity. We suggest that securin immunostaining is a promising and clinically applicable proliferation marker. The finding
urges further prognostic studies with a large sample of patients.
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In breast tumour biology, deregulated proliferation is one of the
most important features predicting malignant behaviour (Desmedt
and Sotiriou, 2006). The prognostic power of mitotic activity and
traditional proliferation markers, such as standardised mitotic
counts and Ki-67, is established in pathological practice. To benefit
individual breast cancer patients, the potential of the traditional
prognostic features could still be intensified by additional methods
(Olivotto et al, 1999; Michels et al, 2003; Oestreicher et al, 2004;
Warwick et al, 2004; Jalava et al, 2006).
We introduce a new proliferation marker, securin (pituitary
tumour-transforming 1 (PTTG1)), which was revealed in cDNA
microarray analysis with a significant change in expression among
several proliferation-related genes studied in invasive ductal breast
cancer. Immunohistochemically, the value of securin as a
proliferation marker was confirmed among the established
proliferation markers of breast cancer. The results emphasise the
potential of securin as a prognostic feature to add information
in identifying a specific subgroup of more favourable outcome in
invasive ductal breast cancer.
MATERIALS AND METHODS
Patient material
The cDNA microarray analysis was performed on 10 patients and
immunohistochemical analysis on 2 patient groups, a total of 44
patients, diagnosed in 1996 and 2004 with invasive ductal breast
cancer in Turku University Hospital, Turku, Finland (Table 1). The
patients were treated with mastectomy with either sentinel lymph
node examination or axillary evacuation, and adjuvant treatment
with anti-oestrogen, trastuzumab or cytostatic drugs depending on
patient’s age, hormone receptor status and CISH-confirmed Her2/
neu oncogene amplification. All patients participated in regular
clinical follow-up during first 5 postoperative years or until the
end point of the study. Complete clinical and follow-up data
starting from date of diagnosis were available from all patients.
Causes of death were verified from autopsy reports, death
certificates and patient files from the Finnish Cancer Registry.
Methods
cDNA microarray analysis In cDNA microarray analysis, special
emphasis was placed on the quality of tissue material. Samples
were obtained fresh from the operation theatre during surgery,
carefully prepared from fat and connective tissue, fresh frozen in
liquid nitrogen and stored at  701C within 30min after surgical
removal. Normal tissue was obtained from benign breast tissue
outside the tumour from five patients to prepare a reference pool
for cDNA microarray analysis. The diagnosis of all samples was
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sverified from a consecutive histological slide. Microarray included
approximately 4000 probes of genes with proven or suspected roles
in human cancer (Turku Centre for Biotechnology, University of
Turku and Abo Akademi University, Turku, Finland). Total RNA
isolation, purification, labelling and microarray hybridisation have
been described previously (Talvinen et al, 2006). Briefly, 21.5mgo f
tumour and reference RNAs was fluorescently labelled (CyDye,
Amersham Biosciences, Buckinghamshire, England) with Cy5 and
Cy3, respectively, during cDNA synthesis using an oligo(dT)
primer (Amersham Biosciences) and Superscript II reverse
transcriptase (Gibco BRL Life Technologies, Rockville, MD,
USA). Hybridisation was performed in a humidified chamber
under LifterSlips (Erie Scientific Company, Portsmouth, NH, USA)
overnight at 651C. Each sample was hybridised once. The
sequences of the relevant up- and downregulated genes were
verified (Turku Centre for Biotechnology).
Immunostainings Immunostainings of securin and Ki-67 were
performed on 4-mm-thick formalin-fixed and paraffin-embedded
sections according to a standard procedure. For securin immuno-
stainings, antigen retrieval was performed by repeated microwave
heating in 10mM sodium citrate buffer (pH 6), with monoclonal
antibody applied manually at a concentration of 1:20 (clone DCS-
280, ab3305, Abcam, Cambridge, UK), and detection was
performed by biotin-avidin reaction (Vectastain ABC reagent,
Vector Laboratories, Burlingame, CA, USA) with diaminobenzi-
dine as chromogen (Sigma, St Louis, MO, USA). Automated
immunostaining machine TechMate 500
þ was used for Ki-67
(clone MIB-1, M 7240, DakoCytomation, Glostrup, Denmark,
concentration 1:100) with the peroxidase/diaminobenzidine
multilink detection kit (DakoCytomation).
Mitotic counts Mitotic counts were determined as mitotic activity
index (MAI) (number of mitoses per 10 high-power fields (HPFs),
450mm in diameter) according to the original publication by Baak
et al (1985).
Evaluation of securin and Ki-67 immunoreactivity, and MAI Evalua-
tion of securin and Ki-67 immunoreactivity, and MAI was
performed on whole carcinoma sections based on the observed
and reported (Ogbagabriel et al, 2005) focal nature of proliferation
in tumour tissue. Securin and Ki-67 immunopositivities were
determined by the fraction (%) of positively stained tumour cells
and securin also by the intensity of staining (0, no staining; 1,
weakly stained; 2, moderately stained; 3, strongly stained) at the
areas of most pronounced staining, usually at the most cellular,
infiltrating border of the tumour. Analysis of Ki-67 positivity was
based on cutoff points at 10 and 20% of cancer cells (Ki-67o10%,
10%pKi-67p20% and Ki-67420%) adopted from clinical prac-
tice and based on research on breast cancer samples from Finland
and other countries (Kronqvist et al, 2004; de Azambuja et al,
2007; Railo et al, 2007). The same cutoff points were applied for
securin immunohistochemistry. Also the cutoff points for MAI
were set at 10 and 20 mitoses in 10 HPFs based on the original
work of Baak et al (1985), the established guidelines of breast
cancer grading (Elston and Ellis, 1991; Tavassoli and Devilee, 2003)
and our previous results on Finnish patients (Kronqvist et al,
2000). The quality of interpretations of immunohistochemistry and
MAI was verified as intra- and interobserver reproducibilities in
repeated evaluations by a single observer or two independent
observers by light microscopy without knowledge of the patients’
clinical data.
Statistical analysis Statistical analysis of cDNA microarray
experiments was performed as described previously (Talvinen
et al, 2006). For each sample, the expression ratio between the
study case and reference pool was determined for each transcript
on the microarray. The expression ratios were log2-transformed
and intensity-normalised with the locally weighted scatter plot
smoothing (LOWESS; Yang et al, 2002). There were three technical
replicates for each transcript on the array. The quality of each spot
was determined visually and the data were preprocessed by
calculating the signal over the whole data so that only spots with
acceptable quality were taken into account. When there were three
proper spots, the median of the replicates was used to calculate the
expression ratio of the transcript. In case of two proper spots, the
mean was used, and in case of only one proper spot the value was
used as such. If no proper spot was found, then the transcript was
marked as missing for the sample under study. Only transcripts
with more than 3 non-missing signal values among the 10 samples
were subjected to statistical analyses. For each transcript, the
preprocessed log-ratios were compared to zero with the one-
sample Student’s t-test. A transcript was considered upregulated if
its mean expression ratio was larger than 0.5 and the P-value of the
t-test was less than 0.05. Similarly, a transcript was considered
downregulated if its mean expression ratio was less than  0.5 and
the P-value was less than 0.05. The resulting gene lists were
examined for biological information in the context of Gene
Ontology by using the GoMiner program package (Zeeberg et al,
2003).
Intraobserver (PK) and interobserver reproducibilities of
immunohistochemical evaluations of securin and Ki-67 (PK and
PH) and evaluation of MAI (PK and JS) described the consistency
of repeated assessments by a single observer or a pair of
independent observers. They were expressed as intraclass correla-
tion coefficients (ICCs) and weighted kappa coefficients (kw) based
on cross-tabulations according to the chosen cutoff points. The
same statistical analyses were applied for intermethod reproduc-
ibilities, and comparisons of the results for securin vs MAI, securin
vs Ki-67 and MAI vs Ki-67 were expressed with the help of scatter
plots.
Prognostic associations between proliferation markers and
survival in breast cancer patients were studied using survival
analysis. The cumulative percentages for survival were estimated
using the Kaplan–Meier technique and the differences in
Table 1 Clinicopathological characteristics of patient material in cDNA
microarrays and immunohistochemistry (IHC)
Microarray (n¼10) IHC (n¼44)
Age at diagnosis (years)
Mean (range) 69 (27–86) 63 (27–87)
Tumour diameter (cm)
Mean (s.d.) 3.2 (1.45) 2.6 (1.68)
Histological grade (%)
I2 0 1 8
II 30 41
III 50 41
Axillary nodal status (%)
Node  30 54
Node+ 70 46
Follow-up time
Mean (range) 2 years and 6 months
(10 months to 3 years
and 5 months)
4 years and 1 month
(10 months to 9 years
and 11 months)
Causes of death
during follow-up
Breast cancer (%) 20 14
Other (%) 10 7
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scumulative percentages between categories were tested using the
log-rank test. Proliferation markers were analysed also with the
Cox regression model as continuous and categorised variables.
Differences were quantified by hazard ratios (HRs) and 95%
confidence intervals (95% CIs). The HRs describe the risk of death
due to breast cancer associated with values of each studied
proliferation marker above the cutoff point as compared with
values below the cutoff point. P-values less than 0.05 were
considered as statistically significant. All statistical computations
were performed with SAS statistical package (SAS Institute, release
8.2.2001, Cary, NC, USA).
RESULTS
cDNA microarray analysis revealed a total of 131 transcripts
upregulated and 256 transcripts downregulated in our sample of
invasive breast cancers, corresponding to 119 and 224 up- and
downregulated genes, respectively. These represented several
significantly deregulated gene groups encoding proteins partici-
pating in DNA replication, regulation of cell proliferation, protein
biosynthesis, superoxide dismutase activity and cytokine produc-
tion. We concentrated on proliferation-related genes, among which
securin showed clear deregulation and the most promising clinical
applications with a consistent immunohistochemical expression
pattern (Figure 1).
In immunohistochemical analysis, the average fraction of
securin-positive cells was 10.9% (range 1.5–34.0) and that of
Ki-67-positive cells 32.4% (range 4.0–80.0). Average MAI was 28.0
mitoses per 10 HPFs (range 2–141 mitoses per 10 HPFs).
Consistency of evaluations as expressed in intra- and interobserver
reproducibilities of each proliferation marker is summarised in
Table 2. In our analysis, the intermethod reproducibility between
MAI and Ki-67 was moderately high (ICC 0.5527, kw 0.2592;
Figure 2A). Interpretations of proliferative activity, however,
differed considerably between securin and MAI (ICC 0.1582,
kw 0.1899; Figure 2B), and between securin and Ki-67 (ICC
 0.2180, kw 0.0619; Figure 2C). In a detailed analysis, securin and
Ki-67 resulted in 75% of cases differently allocated into groups of
low, intermediate and high proliferation. Securin and MAI, in turn,
allocated 64% of cases into different proliferation groups. In our
analysis, the lowest consistency between observed proliferation
rates was found among cases with low (o10%) securin expression
Table 2 Intra- and interobserver reproducibilities of securin and Ki-67
immunohistochemistry, and MAI
Securin Ki67 MAI
ICC jw ICC jw ICC jw
Intraobserver 0.8972 0.7579 0.9577 0.7035 0.9168 0.7632
Interobserver 0.5169 0.3763 0.9286 0.6633 0.9402 0.7484
MAI¼mitotic activity index. The interpretations are expressed as intraclass
correlation coefficients (ICC) and weighted kappa coefficients (kw).
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Figure 2 (A–C) Scatter plots with regression lines demonstrate
differences in intermethod consistency between MAI and Ki-67 immuno-
histochemistry (A), securin immunohistochemistry and MAI (B), and
securin and Ki-67 immunohistochemistry (C) for invasive ductal breast
cancer cases (n¼44).
Figure 1 Securin immunohistochemistry in invasive ductal breast cancer.
The bar represents 50mm.
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sand intermediate or high (X10%) Ki-67 expression (57% of cases),
and low (o10%) securin expression and intermediate or high
(X10%) MAI (45% of cases). Including the evaluation of the
intensity of securin staining in the analysis did not improve
statistical associations.
The results of univariate analysis of Cox’s regression with HRs
of overall risk of death due to breast cancer are summarised in
Table 3 and show statistically significant prognostic value for
securin immunohistochemistry and MAI (HRs 2.3 and 1.3,
respectively). In our sample, only securin immunohistochemistry
demonstrated statistically significant prognostic stratification of
patients according to cutoff points of 10 and 20% of breast cancer
cells. Among the proliferation markers studied, the highest
outcome advantage was associated with securin immunopositivity
(HR 7.1, P¼0.0270, 95% CI 1.3–40.1, securin 420 vs o10%). In
our sample, only securin immunohistochemistry showed statisti-
cally significant prognostic value in Kaplan–Meier survival curves
(P¼0.0112) (Figure 3).
DISCUSSION
Securin is a regulatory protein that plays a central role in DNA
repair, p53/TP53 pathway and chromosome stability (Jallepalli
et al, 2001; Romero et al, 2001; Bernal et al, 2002). Its expression
and localisation are cell cycle-dependent (Yu et al, 2000). Human
cDNA homologous to rat oncoprotein Pttg was first identified by
Dominguez et al (1998). It was soon discovered to be highly
expressed in several carcinoma cell lines and various human
tumours where its abundance was considered as a molecular
marker for aggressive disease (Zhang et al, 1999). In human
tumours, high securin expression has been related to increased cell
proliferation and angiogenic phenotype (Kakar, 1998; Ishikawa
et al, 2001).
Prognostic associations of securin have been reported in
gliomas, and in hepatocellular, thyroid and esophageal carcinomas
(Shibata et al, 2002; Fujii et al, 2006; Genkai et al, 2006). We have
previously described securin expression in a set of genes
aberrantly expressed in colorectal carcinoma as compared to
paired control samples from normal mucosa (Talvinen et al, 2006)
where securin expression was upregulated both at mRNA and
protein levels. The role of securin in breast carcinoma is not
thoroughly studied. Solbach et al (2004) published an initial
observation on securin mRNA overexpression in association with
lymph node involvement and tumour recurrence. In concordance
with our present findings, Ogbagabriel et al (2005) have reported
securin immunohistochemistry in 55 invasive ductal carcinomas
and detected a statistically significant correlation with metastatic
disease, especially in brain metastases. The paper by Ogbagabriel
and co-workers did not analyse associations between securin and
other known proliferation markers.
In the cDNA microarray performed, several proliferation-
associated genes were markedly deregulated in invasive ductal
breast carcinomas (Table 4). According to the magnitude of
expression change, the most significantly deregulated prolifera-
tion-associated genes were topoisomerase DNA II alpha (TOP2A),
securin and insulin-like growth factor 2 (somatomedin A (IGF2)).
The prognostic and therapeutic applications of TOP2A and IGF2
have been extensively studied at tissue mRNA and protein levels
(Sandri et al, 1996; Sachdev and Yee, 2001; Koren et al, 2004). The
observed significant prognostic value of both TOP2A and IGF2 in
our sample supports the reliability of the performed analyses and
urges further evaluation of the prognostic value of securin in
invasive breast cancer.
Based on our results, securin provides a potential proliferation
marker of invasive ductal breast cancer. Comparisons of
proliferation markers indicated that securin immunohistochem-
istry resulted in a different stratification of breast cancer cases,
especially identifying patients with a more favourable prognosis
than the established proliferation markers MAI and Ki-67. In our
sample, a 10-unit increment of securin immunopositivity was
associated with a 2.3-fold overall risk of death due to breast cancer
(P¼0.0218) and a 7.1-fold risk for patients with securin
immunopositivity above 20% compared to below 10%
(P¼0.0270). Further analyses on larger samples of patients are
needed but the present results suggest that securin is a potential
proliferation marker that could in clinical pathology add to the
information of the traditional prognosticators of invasive ductal
breast cancer.
The major shortcomings of the present work are the experi-
mental cDNA microarray methodology and the small sample size
with relatively short follow-up time. However, the present results
confirm and strengthen the previously published experiences on
securin expression in breast cancer (Ogbagabriel et al, 2005). To
compensate for the small number of patients, we have emphasised
the quality of the study material by selecting patients with invasive
ductal carcinomas verified by histology, and up-to date diagnostics
and follow-up from the era of mammographic screening. In
reproducibility analyses between observers and methods, securin
performed acceptably although consistencies in evalutions of
securin immunohistochemistry were not excellent as for the
established methods, MAI and Ki-67. A further point of dispute
could be that, in view of recent publications, MAI is optimal in
prognostication of node-negative breast cancer of patients under
55 years (Louwman et al, 2006; Baak et al, 2007). At the moment,
we are in the process of expanding our experience on securin
immunohistochemistry of invasive and in situ carcinomas in a
larger sample of patients including menopausal and nodal status.
In conclusion, we introduce a new proliferation marker, securin,
which on the basis of biological, immunohistochemical and clinical
data is a promising prognosticator in invasive ductal breast cancer
along with the traditional proliferation markers.
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Figure 3 Kaplan–Meier curves of securin immunohistochemistry
distinguish patients with low (o10% securin immunopositivity), inter-
mediate (10–20% securin immunopositivity) and high (420% securin
immunopositivity) risk of death due to breast cancer (n¼44) (P¼0.0112).
Table 3 Univariate analysis of Cox’s regression performed on 44 cases
of invasive ductal breast cancer for securin and Ki-67 immunohisto-
chemistry, and MAI
P 95% CI HR
Securin 0.0218 1.1–4.6 2.3
Ki-67 0.1581 0.9–2.1 1.4
MAI 0.0227 1.0–1.5 1.3
MAI¼mitotic activity index. The table summarizes P-values with 95% confidence
intervals (95% CI) and hazard ratios (HR) of overall breast cancer death.
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